Literature DB >> 24572192

Clinical practice guidelines for chronic non-malignant pain syndrome patients.

S H Sanders1, K S Rucker2, K O Anderson3, R N Harden4, K W Jackson5, P J Vicente6, R M Gallagher7.   

Abstract

The current paper provides specific guidelines for treating chronic non-malignant pain syndrome patients. The guidelines were developed from an extensive review of existing literature on practice guidelines, the research literature, and common clinical practice across major pain treatment facilities in the USA. They are intended for application to all chronic pain syndrome patients (other than cancer pain) regardless of specific site or etiology of pain. They advocate goal directed treatment to reduce medication misuse and invasive medical procedures, maximize and maintain physical activity, return to productive activity, increase the patient's ability to manage pain, reduce subjective pain intensity, reduce or eliminate the use of healthcare services for primary pain complaint, provide useful information for case settlement, and minimize treatment cost without sacrificing quality. The guidelines recommend interdisciplinary integrated evaluation and treatment on a time limit basis with a focus on conservative medical, psychological behavioral, physical, and vocational interventions based upon the patient's needs. There is emphasis on increasing the patient's level of function and ability to manage pain and related problems. Outpatient care is strongly recommended, with specific upper limits regarding treatment intensity and the use of trigger point injections and nerve blocks delineated. The guidelines also recommend that the long term use of opioid or sedative-hypnotic medications, surgery, implantable spinal devices, or brain stimulation techniques be avoided with chronic pain syndrome patients. These guidelines are intended to serve as a starting point to effectively extend and complement those released by the Agency for Health Care Policy and Research for other types of pain problems such as cancer and acute low back pain.

Entities:  

Keywords:  Chronic pain; Pain rehabilitation; Practice guidelines

Year:  1995        PMID: 24572192     DOI: 10.3233/BMR-1995-5204

Source DB:  PubMed          Journal:  J Back Musculoskelet Rehabil        ISSN: 1053-8127            Impact factor:   1.398


  7 in total

1.  Use of opioids to treat chronic, noncancer pain.

Authors:  B D Dickinson; R D Altman; N H Nielsen; M A Williams
Journal:  West J Med       Date:  2000-02

2.  Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition.

Authors:  R Norman Harden; Candida S McCabe; Andreas Goebel; Michael Massey; Tolga Suvar; Sharon Grieve; Stephen Bruehl
Journal:  Pain Med       Date:  2022-06-10       Impact factor: 3.637

3.  Three patients and their drugs: A parallel case paper on paediatric opiate use and withdrawal.

Authors:  Harold B Siden; Kathleen Collin
Journal:  Paediatr Child Health       Date:  2005-03       Impact factor: 2.253

4.  Laser photobiomodulation is more effective than ultrasound therapy in patients with chronic nonspecific low back pain: a comparative study.

Authors:  Sayed A Tantawy; Walid K Abdelbasset; Dalia M Kamel; Saud M Alrawaili; Saud F Alsubaie
Journal:  Lasers Med Sci       Date:  2018-10-17       Impact factor: 3.161

5.  2-dimensional analysis of low limb taping methods on ambulation for stroke patients.

Authors:  Jung-Ho Lee
Journal:  J Phys Ther Sci       Date:  2017-06-07

Review 6.  Low Back Pain: Current Surgical Approaches.

Authors:  Santosh Baliga; Katrina Treon; Niall John Angus Craig
Journal:  Asian Spine J       Date:  2015-07-28

7.  Effects of photobiomodulation therapy in patients with chronic non-specific low back pain: protocol for a randomised placebo-controlled trial.

Authors:  Shaiane Silva Tomazoni; Lucíola da Cunha Menezes Costa; Layana de Souza Guimarães; Amanda Costa Araujo; Dafne Port Nascimento; Flávia Cordeiro de Medeiros; Marina Athayde Avanzi; Leonardo Oliveira Pena Costa
Journal:  BMJ Open       Date:  2017-10-24       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.